| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2017-02-17 | Swedish Orphan Biovitrum - SOBI (Sweden) Bioverativ (USA - MA) | rFIXFc-XTEN | hemophilia B | collaboration |
Rare diseases - Genetic diseases - Hematological diseases | Collaboration agreement |
| 2017-02-16 | Akcea Therapeutics (USA - CA) Ionis Pharmaceuticals (USA - CA) Novartis (Switzerland) | AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx | development -commercialisation | Cardiovascular diseases | Licensing agreement | |
| 2017-02-16 | Lonza (Switzerland) Selecta Biosciences (USA - MA) | Anc80-AAV-based gene therapy | methylmalonic acidemia | manufacturing bioproduction |
Rare diseases - Genetic diseases | Production agreement |
| 2017-02-16 | Amygdala Neurosciences (USA - CA) Gilead Sciences (USA - CA) | GS-6637 | addiction disorders | product acquisition |
Product acquisition | |
| 2017-02-16 | Catalyst Biosciences (USA - CA) | senior vice-president of technical operations | nomination | Rare diseases - Genetic diseases - Hematological diseases | Nomination | |
| 2017-02-15 | Roche (Switzerland) Medtronic (Ireland) | Accu-Chek Guide Link - Bluetooth Low Energy (BLE) enabled blood glucose monitoring meter | diabetes | collaboration |
Metabolic diseases | Collaboration agreement |
| 2017-02-15 | Boehringer Ingelheim (Germany) Weill Cornell Medicine (USA - NY) | chronic obstructive pulmonary disease (COPD) | R&D |
Inflammatory diseases - Respiratory diseases | R&D agreement | |
| 2017-02-15 | Avexis (USA - IL) | nomination | Nomination | |||
| 2017-02-14 | Vernalis (UK) Corvus Pharmaceuticals (USA - CA) | adenosine receptor antagonist programme including V81444 (CPI-444) | licensing | Cancer - Oncology | Milestone | |
| 2017-02-14 | Servier (France) Gaia (Germany) | deprexis®(internet-based cognitive behavioral therapy) | depression | collaboration |
CNS diseases - Mental diseases | Collaboration agreement |
| 2017-02-14 | Bayer Healthcare (Germany) Ionis Pharmaceuticals (USA - CA) | IONIS-FXIRx | licensing - development - commercialisation | Milestone | ||
| 2017-02-13 | Novasep (France) | viral vector production facility in Seneffe (Belgium) | construction of new premises |
Technology - Services | Construction of new premises | |
| 2017-02-13 | Akebia Therapeutics (USA - MA) Janssen Pharmaceutica, a J&J company (USA - NJ) | HIF-targeting product candidates including AKB-5169 (formerly JNJ5169) | inflammatory bowel disease | licensing |
Inflammatory diseases - Gastrointestinal diseases | Licensing agreement |
| 2017-02-13 | Ferring Pharmaceuticals (Switzerland) Foresee Pharmaceuticals (Taiwan) | long duration, controlled release formulations of a peptide therapeutic | development |
Development agreement | ||
| 2017-02-13 | Inovio Pharmaceuticals (USA - PA) ApolloBio (China) | VGX-3100 | pre-cancerous HPV infections and HPV-driven dysplasias | development commercialisatoin |
Cancer - Oncology - Infectious diseases | Development agreement |
| 2017-02-10 | Noxxon Pharma (Germany) | chief medical officer | nomination | Cancer - Oncology | Nomination | |
| 2017-02-09 | Molecular Partners (Switzerland) | member of the board of directors | nomination | Nomination | ||
| 2017-02-09 | Neurocrine Biosciences (USA - CA) Bial (Portugal) | Ongentys® (opicapone) | licensing | Neurodegenerative diseases | Licensing agreement | |
| 2017-02-08 | Genmab (Denmark) | vice president and chief development officer | nomination | Cancer - Oncology | Nomination | |
| 2017-02-07 | Epizyme (USA - MA) | member of the board of directors | nomination | Cancer - Oncology | Nomination |
